Pharmaceutical Product Monograph: Diacerein Capsules (50 mg)
In the pharmaceutical industry, Diacerein is a unique anthraquinone derivative with potent anti-inflammatory properties. As a pharmacist and manufacturer, I classify this as a SYSADOA (Symptomatic Slow-Acting Drug in Osteoarthritis). It is technically distinct from traditional NSAIDs like Ibuprofen because it does not inhibit prostaglandins; instead, it targets the cellular “master switch” of joint destruction.
At your WHO-GMP facility in Mumbai, Diacerein is a high-value SKU for Orthopedic and Geriatric portfolios. It is the preferred long-term therapy for patients who cannot tolerate the gastric or cardiac risks of chronic NSAID use.
Therapeutic Profile: Primary Indications
Diacerein is specifically indicated for the long-term treatment of degenerative joint diseases.
| Indication | Clinical Context | Technical Rationale |
| Osteoarthritis (OA) | Chronic Management | Specifically effective for OA of the knee and hip, reducing pain and improving joint function. |
| Cartilage Protection | Disease Modifying | Technically slows down the breakdown of the cartilage matrix in the joints. |
| NSAID Sparing | Combination Therapy | Used to reduce a patient’s total daily requirement for “stronger” but riskier painkillers. |
Mechanism: Interleukin-1 (IL-1) Inhibition
Diacerein works by sabotaging the inflammatory cascade at its source:
Metabolic Activation: Diacerein is a prodrug. Once ingested, it is entirely converted into its active metabolite, Rhein, before reaching the systemic circulation.
IL-1 Blockade: Rhein technically inhibits the production and activity of Interleukin-1 beta (IL-1β), the primary cytokine responsible for cartilage destruction and synovial inflammation.
Collagen Protection: By blocking IL-1, it reduces the production of “collagenase” enzymes (Matrix Metalloproteinases) that eat away at the joint lining.
Bypassing COX: Because it does not inhibit Cyclooxygenase (COX), it does not cause stomach ulcers or affect kidney blood flow like regular NSAIDs.
The Pharmacist’s “Technical Warning”
The “Slow-Start” Factor: Diacerein is a slow-acting drug. Patients will not feel pain relief for the first 2–4 weeks. Full clinical benefit usually takes 4–6 weeks of consistent dosing.
The “Discoloration” Side Effect: As a pharmacist, you must warn patients that their urine may turn intense yellow or orange. This is technically harmless (due to the anthraquinone structure) but can be alarming if not explained.
Laxative Effect: The most common side effect is diarrhea (occurring in ~7% of patients). To mitigate this, many protocols suggest starting with 50 mg once daily for the first month before increasing to twice daily.
Liver Monitoring: It is contraindicated in patients with active liver disease or a history of hepatic impairment.
The Manufacturer’s Perspective: Technical & Export
From a production and B2B standpoint at Healthy Life Pharma / Healthy Inc:
The “Safety USP” for Marketing: On your digital marketplace, position Diacerein as the “Gastric-Safe Alternative to NSAIDs.” This is a powerful selling point for B2B buyers catering to elderly populations with sensitive stomachs.
The “Glucosamine” FDC: In many export markets, the “Bestseller” is a Fixed-Dose Combination of Diacerein + Glucosamine + MSM. This offers a “3-in-1” joint support solution that is highly attractive for retail pharmacy chains.
Stability: Diacerein is relatively stable, but for Mumbai-based export, ensure your Alu-Alu blistering is validated. Since the active metabolite is sensitive to pH changes, the integrity of the capsule shell is vital.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Diacerein 50 mg to support your registration in international orthopedic tenders.